Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

28 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Impact of vaccination with third generation modified vaccinia Ankara and sexual behaviour on mpox incidence in men who have sex with men: analysis among participants of the ANRS-174 DOXYVAC trial.
Ghosn J, Assoumou L, Ouattara M, Rubenstein E, Pialoux G, Katlama C, Surgers L, Duvivier C, Pavie J, Viard JP, Algarte-Genin M, Gibowski S, Ollivier M, Costagliola D, Molina JM. Ghosn J, et al. Among authors: gibowski s. Lancet Reg Health Eur. 2024 Aug 1;45:101020. doi: 10.1016/j.lanepe.2024.101020. eCollection 2024 Oct. Lancet Reg Health Eur. 2024. PMID: 39188858 Free PMC article.
Safety and tolerability of immune checkpoint inhibitors in people with HIV infection and cancer: insights from the national prospective real-world OncoVIHAC ANRS CO24 cohort study.
Assoumou L, Baldé R, Katlama C, Abbar B, Delobel P, Allegre T, Lavole A, Makinson A, Zaegel-Faucher O, Greillier L, Soulie C, Veyri M, Bertheau M, Algarte Genin M, Gibowski S, Marcelin AG, Bihan K, Baron M, Costagliola D, Lambotte O, Spano JP. Assoumou L, et al. Among authors: gibowski s. J Immunother Cancer. 2024 Aug 22;12(8):e009728. doi: 10.1136/jitc-2024-009728. J Immunother Cancer. 2024. PMID: 39179255 Free PMC article.
Doxycycline prophylaxis and meningococcal group B vaccine to prevent bacterial sexually transmitted infections in France (ANRS 174 DOXYVAC): a multicentre, open-label, randomised trial with a 2 × 2 factorial design.
Molina JM, Bercot B, Assoumou L, Rubenstein E, Algarte-Genin M, Pialoux G, Katlama C, Surgers L, Bébéar C, Dupin N, Ouattara M, Slama L, Pavie J, Duvivier C, Loze B, Goldwirt L, Gibowski S, Ollivier M, Ghosn J, Costagliola D; ANRS 174 DOXYVAC Study Group. Molina JM, et al. Among authors: gibowski s. Lancet Infect Dis. 2024 Oct;24(10):1093-1104. doi: 10.1016/S1473-3099(24)00236-6. Epub 2024 May 23. Lancet Infect Dis. 2024. PMID: 38797183 Clinical Trial.
Plasma concentrations of antiretroviral drugs in a successful 4-days-a-week maintenance treatment strategy in HIV-1 patients (ANRS 170-Quatuor trial).
Abe E, Landman R, Assoumou L, Amat K, Lambert-Niclot S, Bellet J, Gibowski S, Girard PM, Morand-Joubert L, de Truchis P, Alvarez JC. Abe E, et al. Among authors: gibowski s. J Antimicrob Chemother. 2024 Jun 3;79(6):1380-1384. doi: 10.1093/jac/dkae112. J Antimicrob Chemother. 2024. PMID: 38656448 Clinical Trial.
Immunomodulators for immunocompromised patients hospitalized for COVID-19: a meta-analysis of randomized controlled trials.
Siempos II, Kalil AC, Belhadi D, Veiga VC, Cavalcanti AB, Branch-Elliman W, Papoutsi E, Gkirgkiris K, Xixi NA, Kotanidou A, Hermine O, Porcher R, Mariette X; CORIMUNO-19 Collaborative Group; DisCoVeRy Study Group; ACTT-2 Study Group; ACTT-3 Study Group. Siempos II, et al. EClinicalMedicine. 2024 Feb 9;69:102472. doi: 10.1016/j.eclinm.2024.102472. eCollection 2024 Mar. EClinicalMedicine. 2024. PMID: 38361992 Free PMC article.
Management of pharmacovigilance during the COVID-19 pandemic crisis by the safety department of an academic sponsor: Lessons learnt and challenges from the EU DisCoVeRy clinical trial.
Mercier N, Belhadi D, DeChanet A, Delmas C, Saillard J, Dumousseaux M, Le Mestre S, Fougerou-Leurent C, Ferrane A, Burdet C, Espérou H, Ader F, Hites M, Peiffer-Smadja N, Poissy J, Andrejak C, Paiva JA, Tacconelli E, Staub T, Greil R, Costagliola D, Mentre F, Yazdanpanah Y, Diallo A; DisCoVeRy Safety Working group. Mercier N, et al. Pharmacol Res Perspect. 2023 Jun;11(3):e01072. doi: 10.1002/prp2.1072. Pharmacol Res Perspect. 2023. PMID: 37269068 Free PMC article. Review.
Four days/week antiretroviral maintenance strategy (ANRS 170 QUATUOR): substudies of reservoirs and ultrasensitive drug resistance.
Lambert-Niclot S, Abdi B, Bellet J, Fofana D, De Truchis P, Amat K, Alvarez JC, Surgers L, Allavena C, Zaegell-Faucher O, Morlat P, Palich R, Gibowski S, Costagliola D, Girard PM, Landman R, Assoumou L, Morand-Joubert L; ANRS 170 QUATUOR study group. Lambert-Niclot S, et al. Among authors: gibowski s. J Antimicrob Chemother. 2023 Jun 1;78(6):1510-1521. doi: 10.1093/jac/dkad119. J Antimicrob Chemother. 2023. PMID: 37104815
MOSAIC: a European cohort study of human Mpox - the challenges of clinical research in outbreaks.
Kali S, Bourner J, Calmy A, Laouénan C, Merson L, Cervantes-Gonzalez M, Rojek A, Pesonel E, Guiraud L, Tardivon C, Descamps D, Diallo A, Gibowski S, Rosenthal E, Petrov-Sanchez V, Letrou S, Hoffmann I, Le Mestre S, Mentré F, Yazdanpanah Y, Olliaro P, Lescure FX. Kali S, et al. Among authors: gibowski s. Virologie (Montrouge). 2023 Feb 1;27(1):12-15. doi: 10.1684/vir.2023.986. Virologie (Montrouge). 2023. PMID: 36896770 No abstract available.
[MOSAIC: a European cohort study of human Mpox - the challenges of clinical research in outbreaks].
Kali S, Bourner J, Calmy A, Laouénan C, Merson L, Cervantes-Gonzalez M, Rojek A, Pesonel E, Guiraud L, Tardivon C, Descamps D, Diallo A, Gibowski S, Rosenthal E, Petrov-Sanchez V, Letrou S, Hoffmann I, Le Mestre S, Mentré F, Yazdanpanah Y, Olliaro P, Lescure FX. Kali S, et al. Among authors: gibowski s. Virologie (Montrouge). 2023 Feb 1;27(1):23-26. doi: 10.1684/vir.2023.0985. Virologie (Montrouge). 2023. PMID: 36891777 French. No abstract available.
Implementation of a centralized pharmacovigilance system in academic pan-European clinical trials: Experience from EU-Response and conect4children consortia.
Terzić V, Levoyer L, Figarella M, Bigagli E, Mercier N, De Gastines L, Gibowski S, Trøseid M, Demotes J, Olsen IC, Hites M, Ader F, Lopez JRA, Mentré F, Espérou H, Costagliola D, Røttingen JA, Poissy J, Rozé JC, Warris A, O'Leary J, Fernandes RM, Assoumou L, Hankard R, Turner MA, Yazdanpanah Y, Diallo A; EU-Response safety group; c4c safety group. Terzić V, et al. Among authors: gibowski s. Br J Clin Pharmacol. 2023 Apr;89(4):1318-1328. doi: 10.1111/bcp.15669. Epub 2023 Feb 8. Br J Clin Pharmacol. 2023. PMID: 36680782 Free article. Review.
28 results